title: Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
authors: Rebecca A
authors: RA
authors: Miksad
authors: Lowell
authors: L
authors: Schnipper
authors: Michael
authors: M
authors: Goldstein
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000191:economics; D016527:Drug Costs; D000069347:Erlotinib Hydrochloride; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D019057:Quality-Adjusted Life Years; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D016019:Survival Analysis; D014481:United States; D000093542:Gemcitabine
chemical_list: D011799:Quinazolines; D003841:Deoxycytidine; D000069347:Erlotinib Hydrochloride; D000093542:Gemcitabine